Get started
Author

Claudius Klein

Observed name: Klein, Claudius 1986-
ORCID: 0000-0001-8496-1658
Observed ORCID: 0000-0001-8496-1658
OpenAlex ID: A5112604338
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
2021 · Christine Dierks, Jochen Seufert, et al. · Thyroid · 271
DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas
2016 · Laura Herrtwich, Indrajit Nanda, et al. · Cell · 132
Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
2021 · Kerstin Michalski, Claudius Klein, et al. · Journal of Nuclear Medicine · 48
PDF
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
2016 · Claudius Klein, Anabel Zwick, et al. · The Journal of Experimental Medicine · 39
PDF
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
2023 · Amelie Jaeger, Sudheer Madan Mohan Gambheer, et al. · Blood · 16
Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice
2021 · Lena Osswald, Shaima'a Hamarsheh, et al. · Molecular Cancer Research · 12
PDF
PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion
2019 · Tony Andreas Müller, Sandra Pennisi, et al. · Leukemia · 9
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
2016 · Claudius Klein, Anabel Zwick, et al. · The Journal of Cell Biology · 2
JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL
2024 · Shifa Khaja Saleem, Sarah Decker, et al. · The Journal of Experimental Medicine · 1
PDF
PIM1 Inhibition Enhances and Prolongs Plerixafor-Induced Mobilization of HSCs
2016 · Tony Andreas Müller, Anabel Zwick, et al. · Blood · 1
Depletion of Ptch2 Activates Canonical and Non-Canonical HH Signaling within the Niche Leading to Myeloproliferation, Stem Cell Exhaustion and Accelerates JAK2V617F Driven Disease
2015 · Claudius Klein, Anabel Kuhn, et al. · Blood · 1
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
2024 · Christoph-Ferdinand Wielenberg, Johannes Christian Fostitsch, et al. · Nuklearmedizin - NuclearMedicine
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
2016 · Claudius Klein, Anabel Zwick, et al. · The Journal of Cell Biology
Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma
2015 · Johannes M. Waldschmidt, Dagmar Wider, et al. · Blood
Works count: 16
Citation count: 532
H-index: 7
I10-index: 6
Year
Topic
Type